Introduction

If you have been told you have a hip labrum tear, perhaps with early cartilage wear or femoroacetabular impingement, you may be weighing up whether surgery is truly necessary — or whether a non-surgical option might help first. The answer depends on the extent and location of the damage and whether the joint can be accessed without keyhole surgery. This article explains two distinct pathways available at specialist cartilage centres: the ChondroFiller injection (non-surgical, suited to selected cases of diffuse early wear) and the Liquid Cartilage protocol (keyhole surgery, the more common route for labral and chondral damage in the hip). Understanding which applies to your situation is the first practical step.

The Hip Joint and Why the Labrum Matters

The hip is a deep, ball-and-socket joint that bears the body's full weight through every step. The labrum is a ring of fibrocartilage that deepens the socket, seals the joint space, and helps distribute load evenly across the femoral head. When the labrum is torn or worn — whether from impingement, sport, or gradual degeneration — load is redistributed onto the underlying articular cartilage, accelerating wear and, over time, contributing to early osteoarthritis.

Because the hip sits deep beneath muscle and fascia, reaching the joint surfaces with precision requires either fluoroscopic or arthroscopic guidance. For isolated, diffuse surface-level wear in a well-aligned hip, an ultrasound-guided intra-articular approach may be sufficient. For a discrete chondral defect associated with labral damage — the more common clinical picture — keyhole (arthroscopic) surgery allows the surgeon to prepare the defect site and deliver the scaffold under direct vision.

ChondroFiller: The Scaffold Behind Both Pathways

ChondroFiller is a Class III CE-marked medical device manufactured by Meidrix Biomedicals in Germany. It is an acellular (cell-free) type I collagen hydrogel scaffold that self-gels within approximately three to five minutes of application. Once in place, it acts as a structural framework that attracts the patient's own progenitor cells from surrounding tissue and bone marrow. Over one to two years, the scaffold is gradually resorbed and replaced by the patient's own regenerated tissue. The CE Class III designation, the published safety record, and the outcome data in the literature all belong to ChondroFiller as the device — not to any particular delivery method.

ChondroFiller can be delivered in two fundamentally different ways, and it is important not to conflate them. As a non-surgical ultrasound-guided outpatient injection, it places a regenerative layer over accessible, less severe wear — no theatre, no incision, no general anaesthetic. As part of the Liquid Cartilage surgical protocol, it is introduced arthroscopically into a prepared chondral defect under direct vision, with biological adjuncts to optimise the healing environment. These are distinct procedures with different indications, recovery demands, and goals.

The Liquid Cartilage Protocol for Hip Labral Pathology

The Lee Liquid Cartilage Protocol (LLC Protocol) is Professor Paul Lee's keyhole surgical technique — a holistic, single-stage regenerative system rather than a single product. For the hip, it typically involves arthroscopic access to address the labral pathology and prepare any associated chondral defect, followed by precise delivery of the ChondroFiller scaffold into the defect. This is combined with biological adjuncts — platelet-rich fibrin (PRF) or platelet-rich plasma (PRP), and in selected cases bone-marrow aspirate concentrate (BMAC) or micro-fragmented adipose tissue (mFAT) providing mesenchymal stem cells — to support scaffold integration and regeneration. Tranexamic acid may be used to protect the scaffold in the immediate post-operative period.

Being genuine surgery, the Liquid Cartilage protocol requires a theatre setting, anaesthetic, and a structured rehabilitation programme. For large joints such as the hip, protected weight-bearing with crutches is typically required in the early weeks, with a phased return to activity over several months. This structured recovery is not a limitation of the technique; it is a necessary condition for the scaffold to integrate and for durable repair tissue to form.

In published series of patients treated with ChondroFiller for hip chondral defects, modified Harris Hip Scores (mHHS) have improved by over 30 points and pain scores on the visual analogue scale have shown clinically meaningful reductions. As with any regenerative procedure, outcomes depend on patient selection, defect characteristics, and adherence to rehabilitation. Benefits cannot be guaranteed, and the procedure is not a cure for osteoarthritis.

How ChondroFiller Compares with Conventional Surgical Options

Traditional surgical approaches to chondral defects in the hip include microfracture and autologous chondrocyte implantation (ACI). Microfracture penetrates the subchondral bone to stimulate a repair response, but the tissue formed — fibrocartilage — is mechanically inferior to hyaline cartilage, and clinical benefits often diminish after two to three years. ACI involves two separate surgical stages and lengthy rehabilitation, with significant cost and complexity. The Liquid Cartilage protocol, by contrast, is a single-stage procedure that does not damage the bone plate and is designed to support more durable hyaline-like tissue formation.

Conventional microfracture or debridement at the time of hip arthroscopy for labral repair leaves cartilage defects inadequately addressed. Combining labral management with ChondroFiller scaffold placement under the Liquid Cartilage protocol may reduce the likelihood of progressive wear, though long-term hip-specific evidence is still accumulating and claims of prevention should be treated with appropriate caution.

Who Is Eligible and What Determines the Pathway?

Assessment for either pathway begins with a detailed clinical evaluation, weight-bearing imaging, and MRI to characterise the labrum, the size and depth of any chondral defect, joint alignment, and the degree of arthritis. Broadly:

• The ChondroFiller injection (non-surgical) may be considered for those with early, diffuse surface-level wear, good joint alignment, no discrete full-thickness defect, and who are seeking a non-operative option as a first step.
• The Liquid Cartilage protocol (keyhole surgery) is the more appropriate route when there is a discrete chondral defect associated with labral pathology, when prior conservative measures have been insufficient, or when the hip anatomy requires arthroscopic access for both labral and cartilage treatment.
• Advanced arthritis with significant joint-space narrowing is generally not well suited to either regenerative pathway, and joint replacement assessment may be more appropriate.

Shared decision-making is central to the consultation. The goal is honest communication about what each option can and cannot realistically achieve, not a recommendation of the most technologically advanced treatment for its own sake.

Conclusion

Hip labrum tears with associated chondral damage present a clinical picture that more often calls for keyhole surgical management than for a non-surgical injection alone. The Liquid Cartilage protocol — Professor Lee's arthroscopic technique delivering the ChondroFiller scaffold with biological adjuncts — offers a single-stage, joint-preserving option for eligible patients, with published evidence of meaningful functional improvement. For those with isolated, early, surface-level wear, the ChondroFiller injection provides a non-surgical alternative. The right pathway depends on an accurate assessment of the joint, not on the name of the treatment. The London Cartilage Clinic offers specialist assessment at Harley Street for patients considering either option, with clear guidance on realistic expectations.